Pro-Resolving Mediators in Acute Inflammation in Humans
Status:
Recruiting
Trial end date:
2021-12-15
Target enrollment:
Participant gender:
Summary
The investigators are undertaking a clinical blister model with or without dietary
supplementation with omega-3 fatty acids (i.e., Lovaza) to determine the role of specialized
pro-resolving mediators - endogenous lipids converted from omega-3 fatty acid precursors
including those in Lovaza - on inflammation parameters and their resolution.
Phase:
Early Phase 1
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
National Institute of General Medical Sciences (NIGMS)